Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against BioAge Labs, Inc. due to a class action complaint related to the company's IPO and alleged breaches of fiduciary duties by its board of directors [1] Group 1: Legal Investigation - A class action complaint was filed against BioAge on January 7, 2024, concerning its registration statement for the IPO held on September 26, 2024 [1] - The investigation focuses on whether BioAge's board of directors has breached their fiduciary duties to the company [1] Group 2: Product and Market Impact - On December 6, 2024, BioAge announced the discontinuation of the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety concerns related to elevated liver transaminase levels [2] - This announcement was unexpected, as BioAge had previously highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs during its IPO [2] Group 3: Stock Price Reaction - Following the announcement regarding the discontinuation of the trial, BioAge's stock price fell significantly from $20.09 per share on December 6, 2024, to $4.65 per share on December 7, 2024 [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit related to the company's alleged misleading statements regarding its clinical trials [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][7]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted as part of the trial's design and execution [5]. - The IPO suggested no safety concerns, but the company later discontinued the STRIDES Phase 2 study due to elevated liver enzyme levels in subjects, indicating potential organ damage [6]. Group 3: Allegations of Misleading Information - The lawsuit alleges that BioAge failed to disclose the potential for liver transaminitis from previous clinical trials and preclinical studies, making their statements in the registration statement materially misleading at the time of the IPO [6]. - When the true details about the safety concerns became public, investors reportedly suffered damages [6].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The discontinuation of the STRIDES Phase 2 trial was announced on December 6, 2024, due to elevated liver transaminase levels, causing the stock price to plummet from $20.09 to $4.65 within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4].